Key Takeaways CDTX secured FDA Breakthrough Therapy designation for CD388 to prevent seasonal influenza.The FDA decision follows phase IIb data showing CD388's significant prevention of seasonal influenza.CDTX's ANCHOR phase III study began ahead of schedule and may support regulatory filing if successful.Cidara Therapeutics (CDTX) announced that the FDA has granted a Breakthrough Therapy designation to its lead pipeline candidate, CD388, for the prevention of seasonal influenza.Shares of the company were u ...

SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it will have a late-breaking presentation at the European Scientific Working Group on Influenza (ESWI)’s 10th Influenza Conference taking place October 20-23, 2025 in Valencia, Spain. Presentation details are summarized below: Late-Breaking Abstract Title: Translational efficacy of CD388, a ...

On Thursday, October 9, a wave of strength swept across the biotech and healthcare sectors, with several stocks reaching 52-week highs. The rally was driven by a mix of regulatory milestones, strategic announcements, and investor enthusiasm around clinical progress.Aquestive Therapeutics Inc. (AQST) reached a 52-week high of $6.86 before closing at $6.69 on Thursday. The move followed the company's announcement of a newly issued U.S. patent for its PharmFilm , reinforcing its sway in oral drug delivery pla ...

Breakthrough Therapy designation comes in addition to previously awarded Fast Track designationSAN DIEGO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for CD388 for prevention of influenza A and B in adults and adolescents who are at higher risk of influe ...

SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it has received an award valued up to $339M from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). The multi-year agreement consists of a ...

We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. Cidara Therapeutics, Inc. is one of them. Cidara Therapeutics, Inc. (NASDAQ:CDTX) is a biotechnology company leveraging its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics. Its lead candidate, CD388, is a long-acting antiviral designed to provide universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral replication. In September 2025, CDT ...

Key Points The biotech launched a late-stage trial of a non-vaccine flu preventative. There is a vast addressable market for such a product. 10 stocks we like better than Cidara Therapeutics › Cidara Therapeutics (NASDAQ: CDTX) had some encouraging news to deliver at the end of the trading week, and investors traded the biotech's stock up as a result. It closed Friday nearly 7% higher in price, easily outpacing the 0.6% increase of the bellwether S&P 500 index. Phase 3 trial begins for investigatio ...

Key Takeaways Cidara shares have jumped 217.8% in 2025 so far on progress with its influenza drug candidate CD388.The phase IIb NAVIGATE study met all primary and secondary endpoints across multiple dose levels.The phase III ANCHOR study began ahead of schedule and could support regulatory filing if successful.Shares of Cidara Therapeutics (CDTX) have skyrocketed 217.8% in the year so far, driven by positive updates from the development program of its only clinical-stage pipeline candidate, CD388, for the p ...

- Phase 3 study expected to enroll 6,000 participants starting in the Northern Hemisphere - Participants will include adults over 65 years of age in addition to individuals with high-risk co-morbidities and immune compromised status SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that the first participants have been dosed in its Phase 3 ...

The trial will now include a broader population, such as adults over 65, individuals with high-risk co- morbidities, and those with compromised immune systems. This expansion aims to demonstrate the drug's effectiveness across diverse groups, potentially increasing its market appeal. Currently, CDTX is priced at $88.58, reflecting a 20.53% increase, or $15.09 rise. The stock has fluctuated between $77 and $90.64 today, with the latter being its highest price in the past year. CDTX has a market cap of $2.25 ...